What You Should Know:
– Cala Health, the non-invasive bioelectronic medicine leader, today announced it has raised a $50 million growth round, co-led by Vertex Growth Fund and Nexus NeuroTech Ventures.
– All existing Cala investors participated in the round, including Action Potential, Johnson & Johnson, Lightstone, Lux, GV (Google Ventures), OSF Ventures, Ascension Ventures, TriVentures, Reimagined Ventures, Peak6 and Fiscus.
Cala Health: Revolutionizing Chronic Disease Care with Wearable Neuromodulation
Cala Health is a bioelectronic medicine pioneer transforming chronic disease care with wearable neuromodulation therapies. Combining neuroscience and advanced technology, the company delivers individualized peripheral nerve stimulation through its direct-to-home digital durable medical equipment (DME) platform, reshaping prescription therapy delivery. Founded in 2014 and headquartered in the San Francisco Bay Area, Cala Health is backed by leading healthcare and technology investors and is developing therapies in neurology, cardiology, and psychiatry.
Cala kIQ™: Non-Invasive Relief for Hand Tremors
The Cala kIQ™ System, featuring FDA-cleared Transcutaneous Afferent Patterned Stimulation (TAPS™) therapy, is the only clinically validated non-invasive wearable device for action hand tremor relief in adults with essential tremor (ET) and Parkinson’s disease (PD). Its key features include:
- Individualized stimulation tailored to each patient’s unique tremor signature.
- Temporary relief of postural and kinetic hand tremors affecting daily activities.
- Non-invasive treatment with no systemic side effects, unlike medications or surgical options.
Addressing a Critical Need in Essential Tremor Treatment
Essential tremor affects over 7 million individuals in the United States, impairing critical daily activities. Traditional treatments like medications often result in side effects such as fatigue, nausea, and depression, while invasive options like Deep Brain Stimulation or Focused Ultrasound carry irreversible risks. The Cala kIQ device provides a safer, more accessible alternative, enabling patients to regain control and improve quality of life.
Clinical Evidence and Healthcare Impact
Cala Health is actively building robust clinical evidence to expand access to its neurostimulation therapies. A recent study by CVS Health, presented at the Movement Disorders Congress, demonstrated TAPS therapy’s benefits for essential tremor, including:
- Reduced healthcare resource utilization and costs.
- Improved clinical outcomes and patient quality of life.
Commercial Momentum and Medicare Coverage
Cala Health’s innovative TAPS therapy has gained significant traction, further bolstered by a positive Medicare Coverage Determination. CEO Deanna Harshbarger stated, “This funding round accelerates our commercialization efforts and expands patient and physician awareness of our groundbreaking tremor relief technology. We are thrilled by the strong support from our investors who share our vision.”
By delivering first-in-class, on-demand tremor relief, Cala Health is redefining the treatment landscape for essential tremor and Parkinson’s disease, empowering patients to reclaim their lives.
